Uses and abuses of enzyme therapy in cystic fibrosis

Gaskin K. , Gurwitz D. , Durie P. , Corey M. , Levison H. , Forstner G. Relationship of nutrition and pulmonary function in cystic fibrosis [Letter]. J Pediatr 1983; 103: 164–5.

Kopelman H.R. , Corey M. , Gaskin K.J. , Durie P. , Forstner G.G. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology 1988; 95: 349–55.

Gaskin K.J. , Durie P. , Lee L. , Hill R. , Forstner G.G. Co-lipase and lipase secretion in childhood onset of pancreatic insufficiency: delineation of patients with steatorrhea secondary to relative co-lipase deficiency. Gastroenterology 1984; 86: 1–7.

Waters D.R. , Dorney S.F.A. , Gaskin K.J. , Gruca M.A. , O'Halloran M. , Wilcken B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N Engl J Med 1990; 322: 303–8.

Couper R. Pancreatic Function Tests. In: Walker W.A. , Durie P.R. , Hamilton J.R. , Walker-Smith J.A. , Watkins J.B. , eds. Pediatric Gastrointestinal Disease. Pathophysiology, Diagnosis, Management, 2nd edn. St Louis, MO: Mosby-Year Book Inc., 1996: 1621–34.

DiMagno E.P. , Go V.L.W. , Summerskill W.H.J. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288: 813–15.

Lundh G. Pancreatic function in neoplastic and inflammatory disease: a simple reliable new test. Gastroenterology 1962; 42: 275–80.

Khouri M.R. , Huang G. , Shiau Y.F. Sudan stain of fecal fat: new insight into an old test. Gastroenterology 1989; 96: 421–7.

Colombo C. , Maiavacca R. , Ronchi M. , Consalvo E. , Amoretti M. , Giunta A. The steatocrit: a simple method for monitoring fat malabsorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1987; 6: 926–30.

American Society for Test Materials. Standards for Bomb Calorimetry. Milona, Illinois: Parr Instrument Co, 1974.

van der Kamer J.K. , Huininch H. , Weyers H.A. Rapid method for determining fat in feces. J Biol Chem 1949; 177: 347–55.

Murphy J.L. , Wootton S.A. , Bond S.A. , Jackson A.A. Energy content of stools in normal healthy controls and patients with cystic fibrosis. Arch Dis Child 1991; 66: 495–500.

Dyck W.P. Titremetric measurements of fecal trypsin and chymotrypsin in cystic fibrosis with pancreatic insufficiency. Am J Dig Dis 1967; 12: 310–17.

Remtulla M. , Durie P.R. , Goldberg D.M. Is chymotrypsin output a better diagnostic index than measurement of chymotrypsin in random stool? Enzyme 1988; 39: 190–8.

Stein J. , Jung M. , Sziegolt A. Immunoreactive elastase 1: clinical evaluation of a non-invasive test of pancreatic function. Clin Chem 1996; 42: 222–6.

Soldan W. , Henker J. , Sprössig C. Sensitivity and specificity of quantitative determination of pancreatic elastase 1 in feces of children. J Pediatr Gastroenterol Nutr 1997; 24: 53–5.

Perman J.A. , Montes R.G. Breath tests. In: Walker W.A. , Durie P.R. , Hamilton J.R. , Walker-Smith J.A. , Watkins J.B. , eds. Pediatric Gastrointestinal Disease. Pathophysiology, Diagnosis, Management, 2nd edn. St Louis, MO: Mosby-Year Book, 1996: 1635–45.

Hiele M. , Rutgeerts P. , Vantrappen G. Starch digestion in normal subjects and patients with pancreatic disease using a 13CO₂ breath test. Gastroenterology 1989; 60: 503–9.

Watkins J.B. , Klein P.D. , Schoeller D.A. , Kirschner B.S. , Park R. , Perman J.A. Diagnosis and differentiation of fat malabsorption in children using ¹³C-labelled lipids: Trioctanoin, Triolein and Palmitic acid breath tests. Gastroenterology 1982; 82: 811–907.

Amarri S. , Harding M. , Coward W.A. , Evans T.J. , Weaver L.T. Carbon mixed triglyceride breath test and pancreatic enzyme supplementation in cystic fibrosis. Arch Dis Child 1997; 76: 349–51.

Imondi A.R. , Stradley R.P. , Wolgemuth R. Synthetic peptides in the diagnosis of exocrine pancreatic insufficiency in animals. Gut 1972; 13: 728–31.

Toskes P.P. Bentiromide as a test of pancreatic function in adult patients with pancreatic exocrine insufficiency: determination of appropriate dose and urinary collection interval. Gastroenterology 1983; 85: 565–9.

Weizman Z. , Forstner G.G. , Gaskin K.J. , Kopelman H. , Wong S. , Durie P. The Bentiromide test for assessing pancreatic dysfunction using analysis of PABA in plasma and urine: studies in cystic fibrosis and Shwachman's syndrome. Gastroenterology 1985; 89: 596–604.

Laufer D. , Cleghorn G. , Ellis L. , Koren G. , Forstner G.G. , Durie P.R. The Bentiromide test using plasma PABA for diagnosing pancreatic insufficiency in young children. Gastroenterology 1991; 101: 207–13.

Cleghorn G.J. , Benjamin L. , Forstner G.G. , Dati F. , Durie P. Serum immunoreactive pancreatic lipase and cationic trypsinogen in the assessment of pancreatic function in older patients with cystic fibrosis. Pediatrics 1986; 77: 301–6.

Durie P. , Forstner G.G. , Gaskin K.J. , Moore D.J. , Cleghorn G.J. , Wong S.S. Age-related alterations of immunoreactive pancreatic cationic trypsinogen in sera from CF patients with and without pancreatic insufficiency. Pediatr Res 1986; 20: 209–13.

Couper R.T.L. , Corey M. , Durie P.R. , Forstner G.G. , Moore D.J. Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic sufficient patients with cystic fibrosis. J Pediatr 1995; 127: 408–13.

Kerem E. , Corey M. , Kerem B.S. , Rommens J. , Markiewicz D. , Levison H. The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (ΔF508). N Engl J Med 1990; 323: 1517–22.

Kristidis P. , Bozon D. , Corey M. , Markiewicz D. , Rommens J. , Tsui L-C , Durie P. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992; 50: 1178–84.

Borowitz DS, Grand RJ, Durie PR and the Consensus Committee. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr 1995; 127: 681–4.

Twarog F.J. , Weinstein S.F. , Khaw K-T , Strieder D.J. , Cohen H.R. Hypersensitivity to pancreatic extracts in parents of patients with cystic fibrosis. J Allergy Clin Immunol 1997; 59: 35–40.

Stapleton F.B. , Kennedy J. , Nousia-Arvanitakis S. , Linshaw M.A. Hyperuricosuria due to high dose pancreatic extracts in cystic fibrosis. N Engl J Med 1976; 295: 246–8.

Davidson G.P. , Morad-Hassel F. , Crozier D. , Corey M. , Forstner G. Iatrogenic hyperuricemia in children with cystic fibrosis. J Pediatr 1978; 93: 976–8.

Smyth R.L. , van Velzen D. , Smyth A.R. , Lloyd D.A. , Heaf D.P. Strictures of the ascending colon in cystic fibrosis and high strength enzymes. Lancet 1994; 343: 85–6.

Smyth R.L. , Ashby D. , O'Hea U. Fibrosing colonopathy in cystic fibrosis: results of a case control study. Lancet 1995; 346: 1247–51.

FitzSimmons S.C. , Burkhart G.A. , Borowitz D. High-dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336: 1283–89.

Layer P. , Go V.L.W. , DiMagno E.P. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986; 251: G475–G480.

Thiruvengadam R. , DiMagno E.P. Inactivation of human lipase by proteases. Am J Physiol 1988; 255: G476–G481.

Kraisinger M. , Hochhaus G. , Stecenko A. , Bowser E. , Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994; 34: 158–66.

O'Hare M.M.T. , McMaster C. , Dodge J.A. Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. J Pediatr Gastroenterol Nutr 1995; 21: 59–63.

Graham D.Y. Enzyme replacement therapy of exocrine pancreatic insufficiency in man. N Engl J Med 1977; 296: 1314–17.

DiMagno E.P. , Malagelada J.R. , Go V.L.W. , Moertel C.G. Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two dosage schedules. N Engl J Med 1977; 296: 1318–22.

Zerega J. , Lerner S. , Meyer J.H. Duodenal instillation of pancreatin does not abolish steatorrhea in patients with pancreatic insufficiency. Digest Dis Sci 1988; 33: 1245–9.

Youngberg C.A. , Berardi R.R. , Howatt W.F. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Digest Dis Sci 1987; 32: 472–80.

Robinson P.J. , Smith A.L. , Sly P.D. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Digest Dis Sci 1990; 35: 1299–304.

Graham D.Y. Pancreatic enzyme replacement: the effect of antacids or cimetidine. Digest Dis Sci 1982; 27: 485–90.

Durie P.R. , Bell L. , Linton W. , Corey M.L. , Forstner G.G. Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut 1980; 21: 778–86.

Boyle B.J. , Long W.B. , Balistreri W.F. , Widzer S.J. , Huang N. Effect of cimetidine and pancreatic enzymes on serum and fecal bile acids and fat absorption in cystic fibrosis. Gastroenterology 1980; 78: 950–3.

Cox K.L. , Isenberg J.N. , Osher A.B. , Dooley R.R. The effect of cimetidine on maldigestion in cystic fibrosis. J Pediatr 1979; 94: 488–92.

Schöni M. , Kraemer R. , Ruedeberg A. Long-term cimetidine in children with cystic fibrosis: a randomized double-blind study. Pediatr Res 1984; 18: 66–70.

DiMagno E.P. Controversies in the treatment of exocrine pancreatic insufficiency. Digest Dis Sci 1982; 27: 481–4.

Gow R. , Bradbear R. , Francis P. , Shepherd R.W. Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: effectiveness of an enteric-coated preparation with and without antacids and Cimetidine. Lancet 1981; ii; 1071–4.

Stead R.J. , Skypala I. , Hodson M.E. , Batten J.C. Enteric-coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric-coated preparation. Thorax 1987; 42: 533–7.

Dutta S.K. , Hubbard V.S. , Appier M. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis. Digest Dis Sci 1988; 33: 1237–44.

Beverley D.W. , Kelleher J. , MacDonald A. , Littlewood J.M. , Robinson T. , Walters M.P. Comparison of four pancreatic extracts in cystic fibrosis. Arch Dis Child 1987; 62: 564–8.

Robinson P.J. , Olinsky A. , Smith A.L. , Chitravanshi S.B. High compared with standard dose lipase pancreatic supplement. Arch Dis Child 1989; 64: 143–5.

Brady M.S. , Rickard K. , Yu P-L , Eigen H. Effectiveness and safety of small vs. large doses of enteric coated pancreatic enzymes in reducing steatorrhea in children with cystic fibrosis: a prospective randomized study. Pediatr Pulmonol 1991; 10: 79–85.

Gan K.H. , Heijerman H.G.M. , Geus W.P. , Bakker W. , Lamers C.B.H.W. Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients. Aliment Pharmacol Ther 1994; 8: 603–7.

Lancellotti L. , Cabrini G. , Zanolla L. , Mastella G. High- versus low-lipase acid resistant enzyme preparation in cystic fibrosis: a crossover randomized clinical trial. J Pediatr Gastroenterol Nutr 1996; 22: 73–8.

Meyer J.H. , Elashoff V. , Porter-Fink J. , Dressman , Amidon G.L. Human postprandial gastric emptying of 1–3-millimeter spheres. Gastroenterology 1988; 94: 1315–25.

Ellis L. , Durie P. , Corey M. , Davis L. , Kalnins D. Changing the coating of pancreatic enzyme microspheres to dissolve at a lower pH does not improve efficacy [Abstract]. Pediatr Pulmonol 1994; Suppl 10: 273.

Zentler-Munro P.L. , Fine D.R. , Fitzpatrick W.J.F. , Northfield T.C. Effect of intrajejunal acidity on lipid digestion and aqueous solubilisation of bile acids and lipids in health, using a new simple method of lipase inactivation. Gut 1984; 25: 491–9.

Zentler-Munro P.L. , Fine D.R. , Batten J.C. , Northfield T.C. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 1985; 26: 892–901.

Ellis L. , Kalnins D. , Corey M. , Pencharz P. , Durie P. Correlation between fecal weight, fecal fat and fecal energy in patient with cystic fibrosis [Abstract]. Pediatr Pulmonol 1997; Suppl 14: 307.